Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ: NKTX )

2.330 -0.040 (-1.68%)
Streaming Delayed Price Updated: 9:48 AM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Is Nkarta (NKTX) Stock Soaring 90% Today?
Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial. 
Via InvestorPlace
Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Dow Tumbles Over 300 Points
U.S. stocks opened lower this morning, with the Dow Jones dropping more than 300 points on Monday. 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 25, 2022: Twitter, Coca-Cola, Nkarta, And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items... 
Via Benzinga
How Nkarta Stock Scored A 90% Surge On Its 'Natural Killers' In Cancer
The biotech reported promising results for cell therapies without extreme side effects. 
Via Investor's Business Daily
Why Nkarta Stock Is Soaring Today
Nkarta Inc (NASDAQ: NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dose finding studies. The... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
43 Stocks Moving In Tuesday's Mid-Day Session
Gainers Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
35 Biggest Movers From Friday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
Exposures Product Safety
28 Stocks Moving In Friday's Mid-Day Session
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
Exposures Product Safety
Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022
Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nkarta (NASDAQ:NKTX) shares moved upwards by 8.03% to $30.0 during Thursday's regular session. The current volume of 180.7K shares is 71.9% of Nkarta's... 
Via Benzinga
Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site
Nkarta Therapeutics Inc (NASDAQ: NKTX) will be moving into an 88,000-square-foot facility that will not only serve as its newest headquarters but will support the... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
53 Biggest Movers From Friday
Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform. Vera... 
Via Benzinga
How Much Will the Nkarta Deal Help CRISPR Therapeutics?
Unfortunately, this isn't an endorsement by a big drug developer. 
Via The Motley Fool
Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer
Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Assertio Holdings (NASDAQ:ASRT) shares moved upwards by 32.42% to $0.66 during Friday's pre-market session. The company's market cap stands at $114.5... 
Via Benzinga
74 Biggest Movers From Friday
Gainers MoSys, Inc. (NASDAQ: MOSY) shares climbed 50.5% to settle at $4.35 on Friday. MoSys, last week, reported a loss for its first quarter. HyreCar Inc. (NASDAQ: HYRE) shares... 
Via Benzinga
Fresh Failures
Around the edges, this laughably overvalued stock market is beginning to fray. 
Via Talk Markets
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.